who cannot take glp-1 has changed the conversation around weight loss—but it's important to understand what it can and do. It's not the right choice for everyone, and it's not a replacement for healthy The GLP-1 Solution | Book
Description
Nearly 20% of sites prescribed #GLP-1 receptor agonists based on upper-body photos alone
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
We compare Wegovy, Mounjaro, Saxenda and the new oral pill with clinical data.
If your healthcare professional has recommended supplemental iron or magnesium, Multi+ should not be considered a replacement
2026 updates to cgm, glp-1 ra, sglti, diabetes coverage in Michigan, with the new 2026 PDF MCT2D coverage guide and guidelines that have changed
That's why we built a whole patch around it
